Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
Ajouter des filtres








Gamme d'année
1.
Tuberculosis and Respiratory Diseases ; : 160-167, 2004.
Article Dans Coréen | WPRIM | ID: wpr-191074

Résumé

BACKGROUND: The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy. PATIENTS AND METHODS: We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment. RESULTS: Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. CONCLUSION: ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy.


Sujets)
Humains , Adénocarcinome , Carcinome pulmonaire non à petites cellules , Traitement médicamenteux , Facteur de croissance épidermique , Corée , Tumeurs du poumon , Phosphotransferases , Radiographie , Peau , Carcinome pulmonaire à petites cellules , Thorax
2.
Korean Journal of Medicine ; : 540-544, 2004.
Article Dans Coréen | WPRIM | ID: wpr-214050

Résumé

Multiple pulmonary nodules were found in a 71-year-old Korean female patient with cutaneous squamous cell carcinoma during diagnostic work-up. A presumptive diagnosis of metastases was made and percutaneous fine needle aspiration cytology was undertaken. Finally, pathological examination of the tissue revealed granulomatous inflammation with cryptococcal infection. The patient received 6 months of antifungal treatment with fluconazole and her chest radiographic findings were improved after the treatment. She is now under clinical follow-up. Recognition that pulmonary cryptococcal infection can mimic metastasis is important in reaching the correct diagnosis and in determining the correct treatment.


Sujets)
Sujet âgé , Femelle , Humains , Cytoponction , Carcinome épidermoïde , Cryptococcose , Cryptococcus , Diagnostic , Fluconazole , Études de suivi , Inflammation , Nodules pulmonaires multiples , Métastase tumorale , Radiographie thoracique
3.
Tuberculosis and Respiratory Diseases ; : 579-583, 2004.
Article Dans Coréen | WPRIM | ID: wpr-121412

Résumé

Actinomycosis is an indolent infectious disease characterized by pyogenic response and necrosis, followed by intense fibrosis. The main forms of human actinomycosis are cervicofacial, pulmonary, and abdominopelvic type. Pulmonary actinomycosis accounts for 15% to 20% of total cases and unfortunately, clinical manifestations and radiologic findings are nonspecific. Small pleural effusion or empyema may develop in advanced disease but massive empyema is infrequent and rarely reported. We report a case of huge empyema caused by pulmonary actinomycosis in a 55 year-old man, presented with one-month history of productive cough and fever. The CT scan revealed a huge cavity with air-fluid level occupying the left hemithorax. Empyema caused by actinomycosis was confirmed microscopically by demonstration of sulfur granules in empyema sac through thracotomy. Decortication and surgical resection of empyema sac and destructed lung was accomplished and followed by intravenous infusion of penicillin G.


Sujets)
Humains , Adulte d'âge moyen , Actinomycose , Maladies transmissibles , Toux , Empyème , Fièvre , Fibrose , Perfusions veineuses , Poumon , Nécrose , Benzylpénicilline , Épanchement pleural , Soufre , Tomodensitométrie
4.
The Korean Journal of Internal Medicine ; : 271-275, 2004.
Article Dans Anglais | WPRIM | ID: wpr-85297

Résumé

Department of Protein-losing enteropathy is the manifestation of a diverse set of disorders, and it is characterized by the excessive loss of plasma proteins into the affected portions of the gastrointestinal tract, and this results in hypoalbuminemia. We report here on a case of severe protein-losing enteropathy with the typical clinical features of hypoalbuminemia, dependent edema and increased alpha 1-antitrypsin (alpha1-AT) clearance, as measured by using 24hr stool testing. The associated disorder with the protein-losing enteropathy of our case was radiation enterocolitis and lymphatic obstruction that was due to radiation treatment and lymph node dissection in the remote past for the treatment of uterine cervical carcinoma. Our case suggests that chronic radiation enterocolitis can result in irreversible injury to the intestinal mucosa and a protein-losing enteropathy, which can bring about a very poor quality of life and even the loss of life.


Sujets)
Sujet âgé , Femelle , Humains , Carcinomes/radiothérapie , Tumeurs du col de l'utérus/radiothérapie , Entérocolite/complications , Lymphadénectomie , Maladies lymphatiques/complications , Entéropathie exsudative/étiologie , Radiothérapie/effets indésirables
SÉLECTION CITATIONS
Détails de la recherche